生命科学公司Cytek Biosciences(CTKB)在周一盘中股价大涨33.46%,报收于14.43美元,引发市场广泛关注。导致该公司股价暴涨的主因是其上周五公布的2024年第三季度财报超出市场预期。
CTKB公布,2024年第三季度实现营收5150万美元,同比增长7.3%,超越分析师平均预期;而且公司每股收益1美分,也打破了分析师此前每股亏损1美分的预期。其细胞分析系统Aurora和Northern Lights产品销售强劲是推动业绩增长的主要动力。
尽管受到通胀和汇率波动等不利因素影响,但CTKB仍在产能扩张等领域取得进展,为后续发展夯实基础。公司计划持续深耕细胞分析行业,进一步提升市场份额。投资者看好该公司未来发展前景,故当日股价应声大涨。不过长期来看,该股能否续涨还须考验其盈利的持续性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.